CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, ...

Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...

The influencer has been very open about her journey with Lupus. How Nara Smith's hair and story exemplify the toll on Black ...

AVNS), a medical devices company with annual revenue of $687.8 million and currently trading near its 52-week low of $12.50, has finalized the terms of separation with former executive Michael C.

US-based biopharmaceutical company Cullinan Therapeutics is due to begin a domestic trial of its drug candidate CLN-978 for ...

Greetings and welcome to the Exagen Inc first-quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal ...

The order expressly calls out two organizations that accredit medical schools and residency programs for requiring institutions to have recruitment and retention policies that promote diversity in ...

ALBANY, N.Y. (NEXSTAR) — Democratic state legislators behind the Medical Aid in Dying Act expect its imminent passing in both the Assembly and the Senate. Several of those legislators ...

CLEVELAND, Ohio (WOIO) - Over 160 million dollars in medical debt is gone for more than 160,000 people who live in Cleveland. Two years ago, the Cleveland City Council unanimously passed a measure ...

ALBANY, N.Y. – The Medical Aid in Dying Act has passed the New York State Assembly and now moves on to the State Senate for approval. The bill would allow mentally competent, terminally ill ...

In medical terms, the disease was not treated; it merely retreated under duress. But here is what is most clinically disturbing: There was no apology. No retraction. No penance. No gracious walkback.